title: Tumor necrosis factor alpha 308 G/A polymorphism and Guillain-Barré syndrome risk.
abstract: Guillain-Barré syndrome (GBS) is an inflammatory disorder that may implicate proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) in its pathogenesis. The association between TNF-alpha 308 G/A polymorphism and GBS largely remains unknown. The aim of this study was to investigate the association between TNF-alpha 308 G/A polymorphism and GBS in Chinese Han patients. TNF-alpha 308 G/A polymorphism in 150 GBS patients and 150 healthy controls were studied using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Patients with GBS had a significantly higher frequency of TNF-alpha 308AA genotype [odds ratio (OR) = 3.79, 95% confidence interval (CI) = 1.03, 13.94; P = 0.04] than controls. When stratified by the GBS subtype, there was a significantly higher frequency of TNF-alpha 308AA genotype in patients with AMAN (OR = 6.05, 95% CI = 1.45, 25.31; P = 0.01) and AMSAN (OR = 5.56, 95% CI = 1.18, 26.23; P = 0.03) than controls. There was no significant difference in the distribution of each genotype between patients with AIDP and the control group. These data indicated that TNF-alpha 308AA genotype was associated with a higher risk of GBS in Chinese population, especially to AMAN and AMSAN.
authors: Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, Heilongjiang 150086, People's Republic of China.
authors: Hong
authors: H
authors: Jiao
authors: Weizhi
authors: W
authors: Wang
authors: Huabing
authors: H
authors: Wang
authors: Yun
authors: Y
authors: Wu
authors: Lihua
authors: L
authors: Wang
references: Eur Neurol. 2007;57(4):203-7
references: 17268200
references: Microsc Res Tech. 2000 Aug 1;50(3):216-28
references: 10891887
references: Brain. 1995 Aug;118 ( Pt 4):869-78
references: 7655885
references: Curr Opin Pharmacol. 2004 Aug;4(4):314-20
references: 15251122
references: Am J Gastroenterol. 2003 May;98(5):1101-6
references: 12809834
references: J Neuroimmunol. 2005 May;162(1-2):157-64
references: 15833371
references: J Leukoc Biol. 1999 Oct;66(4):562-6
references: 10534109
references: Cancer Causes Control. 2004 Sep;15(7):657-63
references: 15280623
references: Acta Neurol Scand. 2010 Jul;122(1):21-6
references: 20105138
references: J Neurol Sci. 1992 Mar;108(1):99-104
references: 1378089
references: Ann Neurol. 1990;27 Suppl:S21-4
references: 2194422
references: Mol Immunol. 1997 Apr;34(5):391-9
references: 9293772
references: Neurology. 2001 Mar 27;56(6):758-65
references: 11274311
references: Hum Immunol. 2001 Nov;62(11):1191-9
references: 11704281
references: J Neuroimmunol. 1999 Dec;100(1-2):74-97
references: 10695718
references: Brain. 1995 Jun;118 ( Pt 3):597-605
references: 7600081
references: Clin Biochem. 2008 Jul;41(10-11):881-6
references: 18472000
references: Thorax. 2006 Jun;61(6):466-71
references: 16517578
references: J Neuroimmunol. 2010 Jan 25;218(1-2):116-9
references: 19913922
references: Eur Neurol. 2007;58(1):21-5
references: 17483581
references: J Neuroimmunol. 2009 Dec 10;217(1-2):80-4
references: 19853929
references: Hum Immunol. 2010 Sep;71(9):905-10
references: 20600447
references: J Neuroimmunol. 2003 Jun;139(1-2):81-3
references: 12799024
references: Eur Neurol. 2003;50(1):25-9
references: 12824709
references: J Neuroimmunol. 2007 Oct;190(1-2):127-30
references: 17761309
references: Hum Mol Genet. 1992 Aug;1(5):353
references: 1363876
references: Ann Neurol. 1998 Nov;44(5):780-8
references: 9818934
references: J Neuroimmunol. 2007 Dec;192(1-2):206-14
references: 17997492
references: Ann Neurol. 1996 Jan;39(1):17-28
references: 8572662
references: Ann Neurol. 1993 Jun;33(6):591-6
references: 8498839